Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trialThomas L Holland, Robert C. Hyzy, Andrew M. Vekstein et al.|The Lancet Respiratory Medicine|2022Cited by 127
Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)Iván O. Rosas, Min Bao, Norbert Bräu et al.|EClinicalMedicine|2022Cited by 37
WED-005 Current hepatitis D virus infection prevalence in persons with human immunodeficiency virus and hepatitis B virus across EuropeAnders Boyd, Pablo Ryan, Lutz Thomas et al.|Journal of Hepatology|2025Cited by 1